Richard Y. Cheng's practice focuses on corporate transactions, regulatory, compliance matters and administrative appeals. He has an extensive healthcare law practice, with particular concentration representing post-acute care providers (e.g. nursing facilities, hospices, home health care agencies, hospices, rehabilitation providers), community hospitals, physician groups, ancillary providers, retail medicine providers, management service organizations (MSOs), dental service organizations (DSOs) regulated products providers (e.g. hemp based businesses), private equity groups and investors.

Richard has considerable experience representing clients involving Stark Law, Anti-Kickback Statute, FCA, EKRA, HIPAA, HITECH Act, Civil Monetary Penalties (CMPs), state based healthcare regulations, Medicare-related transactions (e.g. change of ownership) licensure surveys, formation of MSOs and DSOs, managed care organization (MCO) payment matters, Medicaid contracting and Medicare appeals before administrative law judges.

Richard formerly served as vice president and general counsel at two separate healthcare companies, where he assisted with change of ownership transactions, counseled on healthcare operational matters and worked closely with outside counsel managing multiple litigation matters. He also created the medical appeals departments at both healthcare organizations, overseeing multiple staff members that he trained, resulting in the successful recover of millions of dollars in governmental and private healthcare insurance claims. Early in his career, Richard worked as a licensed occupational therapist, served as an adjunct faculty at multiple universities and lobbied in Washington D.C. through the American Occupational Therapy Association.

In addition to his traditional healthcare practice, Richard developed a cannabis regulatory and corporate practice starting in late 2013. He formerly served as outside general counsel to the Texas Cannabis Industry Association, co-authored a FDA primer in preparation for the 2019 FDA public hearing on CBD products and currently serve as an advisory board member to a hemp pharmaceutical development company. Richard represents and regularly advises a broad base of cannabis related clients, including, physicians, private equity groups investing in the cannabis industry, cultivators, processors, wholesalers, retailers, distribution centers and ancillary providers (e.g. testing labs, biomass brokerage firms, etc.) in regulatory and corporate matters.